Ophthalmologic Involvement in Adults with Histiocytic Disorders: Clinical Presentation and Treatment Outcomes.

Robert Vassallo, W Oliver Tobin, James A Garrity, Karen L Rech, Mithun V Shah, N Nora Bennani, Julio C Sartori Valinotti, Aishwarya Ravindran, Caroline J Davidge-Pitts, Jay H Ryu, Samantha A Banks, Matthew J Koster, Jason R Young, Gaurav Goyal, Antonious Z Hazim, Aldo A Acosta-Medina, Jithma P Abeykoon, Ronald S Go, M Tariq Bhatti

Journal: Ophthalmology 2022;130(1):77-86

PMID: 35932838

Abstract

PURPOSE

To evaluate the clinical presentation, treatment, and outcomes in adult patients with histiocytic disorders with ocular, orbital, optic nerve, or cavernous sinus involvement.

DESIGN

Observational, retrospective chart review.

PARTICIPANTS

Adult patients (age ≥ 18 years) at Mayo Clinic from January 1, 1996, to July 1, 2021, with histiocytic disorders. Inclusion criteria were (1) histiocytic disorder by biopsy and appropriate clinical phenotype; (2) available medical records; and (3) ocular, orbital, optic nerve, or cavernous sinus involvement.

METHODS

Retrospective chart review.

MAIN OUTCOME MEASURES

Response to therapy, measured in clinical and radiographic impact.

RESULTS

Thirty-two patients were identified: 7 with Langerhans cell histiocytosis (LCH); 15 with Erdheim-Chester disease (ECD); 1 with mixed LCH/ECD phenotype; 8 with Rosai-Dorfman disease (RDD); and 1 with mixed RDD/ECD phenotype. Ophthalmologic involvement was part of the initial presentation in 69% of patients (22/32). Eyelid edema (13/32, 41%) and proptosis (12/32, 38%) were the most frequent presentations. Isolated orbital or cavernous sinus involvement was present in 3 of 7 patients with LCH and 1 of 8 patients with RDD. Optic nerve sheath involvement was present in 2 of 7 LCH patients, 14 of 15 ECD patients, and 1 RDD/ECD patient. Diffuse (> 75%) orbital involvement was seen in 12 of 15 ECD patients and 1 of 7 LCH patients. Ocular involvement was seen in 1 of 15 ECD patients, 6 of 8 RDD patients, and 1 of 1 mixed RDD/ECD patient. The cavernous sinuses were involved in 1 of 7 LCH patients, 5 of 15 ECD patients, and both mixed phenotype patients. Visual acuity was affected in 14 patients (14/24, 58%) with a median logarithm of the minimum angle of resolution visual acuity of 0.1 (range, -0.12 to 3). BRAF V600E mutations were found in 75% (3/4) of LCH patients and 91% (10/11) of ECD patients. Patients received a variety of treatment, and response was variable across disease types.

CONCLUSIONS

Orbital involvement was more commonly seen in LCH and ECD, whereas ocular involvement was more common in RDD. Visual acuity may be impacted from ocular involvement or compression of the optic nerve with diffuse orbital involvement.

Copyright © 2022 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Address: Division of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota.; Division of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota; Division of Ophthalmology, Mayo Clinic College of Medicine, Rochester, Minnesota.; Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota.; Division of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota.; Division of Hematology-Oncology, University of Alabama at Birmingham, Birmingham, Alabama.; Division of Radiology, Mayo Clinic College of Medicine, Rochester, Minnesota.; Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, Minnesota.; Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota.; Division of Endocrinology, Diabetes, and Nutrition, Mayo Clinic College of Medicine, Rochester, Minnesota.; Division of Hematopathology, Mayo Clinic College of Medicine, Rochester, Minnesota.; Division of Dermatology, Mayo Clinic College of Medicine, Rochester, Minnesota.; Division of Ophthalmology, Mayo Clinic College of Medicine, Rochester, Minnesota.; Division of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota. Electronic address: [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.